Jan 11, 2018 · Despite its high prevalence, there is surprisingly limited evidence to inform best clinical practice both at the time of …

There is a risk that MGUS develops into a malignancy (myeloma or lymphoma) or alternatively conditions related to the M-protein …

Oct 1, 2025 · No therapy is needed for MGUS, and the schedule for clinical follow-up is dictated by underlying risk stratification.

What is the aim of the low-risk MGUS pathway? To safely monitor the monoclonal gammopathy patient cohort with the lowest risk of …

Nov 5, 2024 · This retrospective real-world study informs a proposed framework of patient centred, fixed duration monitoring for lower …

Jan 17, 2018 · We present the results of a study of the rates of progression and survival associated with IgM and non-IgM MGUS in a …

Sep 9, 2025 · Monitoring MGUS: Risk-Stratified Approach The recommended approach for monitoring Monoclonal Gammopathy of …

Given current NHS resource limitations, ongoing monitoring for MGUS cannot be offered at this time, however, should the patient …

It may also prove useful in identifying patients with a very low risk of malignant transformation and less intensive follow-up (BCSH …

Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every two to three years …